Repligen Co. (NASDAQ:RGEN) Shares Acquired by Curi RMB Capital LLC

Curi RMB Capital LLC raised its stake in Repligen Co. (NASDAQ:RGEN) by 0.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 113,212 shares of the biotechnology company’s stock after acquiring an additional 685 shares during the quarter. Curi RMB Capital LLC owned approximately 0.20% of Repligen worth $16,848,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. Zions Bancorporation N.A. raised its holdings in Repligen by 20.5% in the 3rd quarter. Zions Bancorporation N.A. now owns 9,453 shares of the biotechnology company’s stock worth $1,407,000 after purchasing an additional 1,608 shares during the period. Oppenheimer Asset Management Inc. raised its stake in shares of Repligen by 7.2% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 20,985 shares of the biotechnology company’s stock worth $3,123,000 after buying an additional 1,411 shares during the period. Geneva Capital Management LLC lifted its position in shares of Repligen by 8.5% during the 3rd quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company’s stock valued at $20,638,000 after buying an additional 10,908 shares in the last quarter. WCM Investment Management LLC grew its position in shares of Repligen by 47.9% in the third quarter. WCM Investment Management LLC now owns 99,158 shares of the biotechnology company’s stock valued at $14,470,000 after purchasing an additional 32,126 shares during the period. Finally, Versor Investments LP acquired a new position in shares of Repligen during the 3rd quarter worth about $893,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Stock Performance

Shares of RGEN stock opened at $150.47 on Thursday. The firm has a market cap of $8.43 billion, a P/E ratio of -406.66, a P/E/G ratio of 4.27 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. Repligen Co. has a one year low of $113.50 and a one year high of $211.13. The firm’s 50 day moving average price is $141.59 and its 200-day moving average price is $144.78.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The business had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same period in the previous year, the firm posted $0.23 earnings per share. The company’s revenue was up 9.7% on a year-over-year basis. As a group, equities research analysts predict that Repligen Co. will post 1.45 EPS for the current year.

Insiders Place Their Bets

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

RGEN has been the topic of several research analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. Wolfe Research assumed coverage on shares of Repligen in a research report on Thursday. They issued a “peer perform” rating for the company. JPMorgan Chase & Co. raised their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 31st. Stephens reissued an “overweight” rating and set a $170.00 price objective on shares of Repligen in a research note on Tuesday, July 30th. Finally, Benchmark restated a “hold” rating on shares of Repligen in a report on Monday, August 5th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $190.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.